Analysts Issue Forecasts for Regulus Therapeutics Inc.’s FY2023 Earnings (NASDAQ:RGLS)

Regulus Therapeutics Inc. (NASDAQ:RGLSGet Rating) – Equities researchers at Cantor Fitzgerald issued their FY2023 earnings per share estimates for shares of Regulus Therapeutics in a research note issued to investors on Monday, June 6th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the biopharmaceutical company will post earnings per share of ($0.21) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock.

RGLS has been the subject of a number of other research reports. StockNews.com initiated coverage on shares of Regulus Therapeutics in a research report on Monday. They set a “sell” rating for the company. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th.

RGLS opened at $0.25 on Thursday. The firm has a 50 day moving average price of $0.24 and a 200 day moving average price of $0.27. The company has a market cap of $36.93 million, a PE ratio of -0.84 and a beta of 2.18. Regulus Therapeutics has a 1 year low of $0.16 and a 1 year high of $1.48. The company has a debt-to-equity ratio of 0.07, a quick ratio of 12.32 and a current ratio of 12.32.

Regulus Therapeutics (NASDAQ:RGLSGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). During the same quarter last year, the company posted ($0.08) EPS.

Several institutional investors have recently added to or reduced their stakes in RGLS. Northern Trust Corp lifted its stake in Regulus Therapeutics by 42.9% during the first quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 50,518 shares during the last quarter. Morgan Stanley grew its holdings in Regulus Therapeutics by 13.0% during the third quarter. Morgan Stanley now owns 564,462 shares of the biopharmaceutical company’s stock worth $390,000 after acquiring an additional 64,837 shares during the period. Geode Capital Management LLC boosted its position in shares of Regulus Therapeutics by 13.8% in the 3rd quarter. Geode Capital Management LLC now owns 670,747 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 81,551 shares during the period. Renaissance Technologies LLC boosted its position in shares of Regulus Therapeutics by 498.2% in the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 111,100 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Regulus Therapeutics by 21.4% in the 1st quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 648,121 shares during the period. Institutional investors own 47.06% of the company’s stock.

Regulus Therapeutics Company Profile (Get Rating)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Featured Articles

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.